Literature DB >> 28186662

Blepharospasm 40 years later.

Giovanni Defazio1, Mark Hallett2, Hyder A Jinnah3, Antonella Conte4,5, Alfredo Berardelli4,5.   

Abstract

Forty years ago, C.D. Marsden proposed that blepharospasm should be considered a form of adult-onset focal dystonia. In the present paper, we provide a comprehensive overview of the findings regarding blepharospasm reported in the past 40 years. Although prolonged spasms of the orbicularis oculi muscles remain the clinical hallmark of blepharospasm, patients with blepharospasm may be characterized by various types of involuntary activation of periocular muscles. In addition to motor features, blepharospasm patients may also have nonmotor manifestations, including psychiatric, mild cognitive, and sensory disturbances. The various motor and nonmotor symptoms are not present in all patients, suggesting that blepharospasm is phenomenologically a heterogeneous condition. This emphasizes the need for tools for severity assessment that take into account both motor and nonmotor manifestations. The cause of blepharospasm remains elusive, but several lines of evidence indicate that blepharospasm is a multifactorial condition in which one, or several, as yet unknown genes together with epigenetic and environmental factors combine to reach the threshold of the disease. Although blepharospasm was originally believed to be solely a basal ganglia disorder, neurophysiological and neuroimaging evidence point to anatomical and functional involvement of several brain regions. The contribution of multiple areas has led to the hypothesis that blepharospasm should be considered as a network disorder, and this might reflect the varying occurrence of motor and nonmotor manifestations in blepharospasm patients. Despite advances in the aetiology and pathophysiology, treatment remains symptomatic.
© 2017 International Parkinson and Movement Disorder Society. © 2017 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  blepharospasm; clinical features; dystonia; pathophysiology

Mesh:

Year:  2017        PMID: 28186662      PMCID: PMC5941939          DOI: 10.1002/mds.26934

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  129 in total

1.  The effect of nocturnal physiological sleep on various movement disorders.

Authors:  R Silvestri; P De Domenico; A E Di Rosa; P Bramanti; S Serra; R Di Perri
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

2.  Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up.

Authors:  Juan Ramirez-Castaneda; Joseph Jankovic
Journal:  Toxicon       Date:  2014-08-15       Impact factor: 3.033

3.  Animal model explains the origins of the cranial dystonia benign essential blepharospasm.

Authors:  E J Schicatano; M A Basso; C Evinger
Journal:  J Neurophysiol       Date:  1997-05       Impact factor: 2.714

4.  Analysis of open-label trials in torsion dystonia using high dosages of anticholinergics and other drugs.

Authors:  P Greene; H Shale; S Fahn
Journal:  Mov Disord       Date:  1988       Impact factor: 10.338

5.  Higher prevalence of obsessive-compulsive symptoms in patients with blepharospasm than in patients with hemifacial spasm.

Authors:  A Broocks; A Thiel; D Angerstein; D Dressler
Journal:  Am J Psychiatry       Date:  1998-04       Impact factor: 18.112

6.  Risk factors for spread of primary adult onset blepharospasm: a multicentre investigation of the Italian movement disorders study group.

Authors:  G Defazio; A Berardelli; G Abbruzzese; V Coviello; F Carella; M T De Berardinis; G Galardi; P Girlanda; S Maurri; M Mucchiut; A Albanese; M Basciani; L Bertolasi; R Liguori; N Tambasco; L Santoro; G Assennato; P Livrea
Journal:  J Neurol Neurosurg Psychiatry       Date:  1999-11       Impact factor: 10.154

Review 7.  Consensus paper on short-interval intracortical inhibition and other transcranial magnetic stimulation intracortical paradigms in movement disorders.

Authors:  Alfredo Berardelli; Giovanni Abbruzzese; Robert Chen; Michael Orth; Michael C Ridding; Cathy Stinear; Antonio Suppa; Carlo Trompetto; Philip D Thompson
Journal:  Brain Stimul       Date:  2008-07-01       Impact factor: 8.955

8.  Coexistent Meige's syndrome and myasthenia gravis. A relationship between blinking and extraocular muscle fatigue?

Authors:  R Kurlan; J Jankovic; A Rubin; B Patten; R Griggs; I Shoulson
Journal:  Arch Neurol       Date:  1987-10

9.  Executive functioning in patients with blepharospasm in comparison with patients with hemifacial spasm.

Authors:  Fernando Machado Vilhena Dias; Flávia C P Doyle; Arthur Kummer; Francisco Cardoso; Paulo Caramelli; Antônio Lúcio Teixeira
Journal:  Arq Neuropsiquiatr       Date:  2009-03       Impact factor: 1.420

10.  Anatomical correlates of blepharospasm.

Authors:  Silvina G Horovitz; Anastasia Ford; Muslimah Ali Najee-Ullah; John L Ostuni; Mark Hallett
Journal:  Transl Neurodegener       Date:  2012-06-15       Impact factor: 8.014

View more
  34 in total

1.  BDNF rs6265 (Val66Met) Polymorphism as a Risk Factor for Blepharospasm.

Authors:  Vasileios Siokas; Dimitrios Kardaras; Athina-Maria Aloizou; Ioannis Asproudis; Konstadinos G Boboridis; Eleni Papageorgiou; Georgios M Hadjigeorgiou; Evangelia E Tsironi; Efthimios Dardiotis
Journal:  Neuromolecular Med       Date:  2018-12-05       Impact factor: 3.843

2.  Long-term treatment of blepharospasm with botulinum toxin A: a service-based study over a 16-year follow-up in southern China.

Authors:  Xiao-Bo Fang; Meng-Shu Xie; Zu-Biao Song; Zhi-Gang Zhong; Ying Wang; Zi-Lin Ou; Chao Dang; Ling Li; Wei-Xi Zhang
Journal:  Neurol Sci       Date:  2019-11-19       Impact factor: 3.307

3.  Treatment of blepharospasm and Meige's syndrome with abo- and onabotulinumtoxinA: long-term safety and efficacy in daily clinical practice.

Authors:  Angela Jochim; Tobias Meindl; Christoph Huber; Tobias Mantel; Silke Zwirner; Florian Castrop; Bernhard Haslinger
Journal:  J Neurol       Date:  2019-10-19       Impact factor: 4.849

4.  Motor and non-motor symptoms in blepharospasm: clinical and pathophysiological implications.

Authors:  Gina Ferrazzano; Isabella Berardelli; Antonella Conte; Viola Baione; Cristina Concolato; Daniele Belvisi; Giovanni Fabbrini; Giovanni Defazio; Alfredo Berardelli
Journal:  J Neurol       Date:  2019-07-29       Impact factor: 4.849

5.  Blepharospasm: A genetic screening study in 132 patients.

Authors:  Monia Hammer; Alexandra Abravanel; Elizabeth Peckham; Ava Mahloogi; Elisa Majounie; Mark Hallett; Andrew Singleton
Journal:  Parkinsonism Relat Disord       Date:  2019-04-02       Impact factor: 4.891

6.  Soft Nanomembrane Sensors and Flexible Hybrid Bioelectronics for Wireless Quantification of Blepharospasm.

Authors:  Musa Mahmood; Shinjae Kwon; Gamze Kilic Berkmen; Yun-Soung Kim; Laura Scorr; H A Jinnah; Woon-Hong Yeo
Journal:  IEEE Trans Biomed Eng       Date:  2020-02-21       Impact factor: 4.538

7.  Blepharospasm in Japan: A Clinical Observational Study From a Large Referral Hospital in Tokyo.

Authors:  M Wakakura; A Yamagami; M Iwasa
Journal:  Neuroophthalmology       Date:  2018-01-09

8.  The Use of Botulinum Toxin for Treatment of the Dystonias.

Authors:  Alfredo Berardelli; Antonella Conte
Journal:  Handb Exp Pharmacol       Date:  2021

Review 9.  Treatment of Blepharospasm/Hemifacial Spasm.

Authors:  Kemar E Green; David Rastall; Eric Eggenberger
Journal:  Curr Treat Options Neurol       Date:  2017-09-30       Impact factor: 3.598

Review 10.  The role of sensory information in the pathophysiology of focal dystonias.

Authors:  Antonella Conte; Giovanni Defazio; Mark Hallett; Giovanni Fabbrini; Alfredo Berardelli
Journal:  Nat Rev Neurol       Date:  2019-04       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.